NCT06119256View on ClinicalTrials.gov

Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
EBV Infection After Allogenic HSCT
Interventions
BIOLOGICAL

EBV-TCR-T cells

The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\^5/kg to 1×10\^6/kg EBV-TCR-T cells per dose.

Trial Locations (1)

100853

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER